Roche buys Hansoh’s CDH17 ADC rights: $80M upfront, $1.45B milestones

Roche agreed to acquire global rights to Hansoh Pharma’s early‑stage antibody‑drug conjugate targeting CDH17 in colorectal cancer, paying $80 million upfront and up to $1.45 billion in milestones. The deal gives Roche an ADC candidate focused on a validated solid‑tumor antigen and expands its oncology payloads and targeting strategies. Antibody‑drug conjugates (ADCs) link tumor-targeting antibodies to cytotoxic payloads to deliver cell‑killing agents selectively. The transaction underscores continued Big Pharma investment in ADC platforms for difficult solid tumors.